We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
Information for patients, healthcare professionals and developers of new medicines
Pharmacy, prescription-only (POM), and general sale list (GSL) medicines: apply to move your medicine to a different classification.
Substances that are classed as persistent organic pollutants (POPs) and when you're allowed to use them.
Information on good laboratory, manufacturing and distribution practice, good pharmacovigilance practice (GPvP), out-of-specification investigations, inspection metrics and fees.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
British Pharmacopoeia (BP) provides official standards for pharmaceutical substances and medicinal products. British Pharmacopoeia Commission is an advisory non-departmental public body, sponsored by the Department of Health and Social Care .
Applications received to amend the specification of a patent under sections 27 and 75 before the court and the Office.
Urgent safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.
The New Active Substance Work Sharing Initiative (NASWSI) has successfully approved several medicines through this international collaboration and continues to foster cooperation and strong relationships between its Access partners. The Biosimilar Work Sharing Initiative (BSWSI) builds on this success.
The CMA investigated alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.
Information about when you need to submit substantial amendments to a clinical trial including changes to the trial sponsor or legal representative, Investigational medicinal product certification and importation.
Information on carrying medicine containing controlled drugs for individual travellers entering or leaving the UK.
How to show MHRA you're meeting good clinical practice (GCP) standards and what to expect from an inspection.
Novartis Pharmaceuticals UK Limited is recalling Adakveo 10 mg/ml concentrate for solution for infusion due to the benefit-risk balance of Adakveo no longer being considered favourable by the MHRA.
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
Guidance for the veterinary pharmaceutical industry on the production and submission of the Summary of Product Characteristics (SPCs) and product literature mock-ups.
Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.